GuidelinesOther guideline
Oropharyngeal Candida
Infection Oropharyngeal Candida Brief outline/clinical setting Oropharyngeal and/or oesophageal candidiasis usually occurs in association with underlying HIV infection, diabetes, leukaemia, antimicrobial therapy, steroid use and denture use. In HIV-infected patients, oropharyngeal candidiasis usually occurs in in patients with CD4 counts < 200 cells/µl. Most patients with oropharyngeal c
| Infection | Oropharyngeal Candida |
| Brief outline/clinical setting | Oropharyngeal and/or oesophageal candidiasis usually occurs in association with underlying HIV infection, diabetes, leukaemia, antimicrobial therapy, steroid use and denture use. In HIV-infected patients, oropharyngeal candidiasis usually occurs in in patients with CD4 counts < 200 cells/µl. Most patients with oropharyngeal candida respond initially to topical therapy. In HIV-infected patients, fluconazole is more effective than topical treatment to prevent relapses. |
| Aetiologies/organisms | Candida albicans – majority of cases |
| Optimal antimicrobial selection |
Mild disease: Moderate to severe disease: |
| Duration | 7 – 14 days |
| Alternative if allergic/not available | Mild disease: Nystatin suspension (100 000IU) 4-6ml four times daily See guidelines for other treatment options |
| Rationale | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Level of evidence | Strong, high quality evidence |
| Link to Guideline |